The POPCaP Act of 2026 establishes a national precision oncology program within the Department of Veterans Affairs to improve prostate cancer care through specialized centers of excellence, advanced genetic research, and clinical trials.
Jerry Moran
Senator
KS
The POPCaP Act of 2026 establishes a precision oncology program within the Department of Veterans Affairs to improve prostate cancer care for veterans. The bill mandates the creation of a national network of centers of excellence, supported by a centralized leadership team, to provide advanced genetic sequencing, clinical trials, and specialized research. This initiative aims to standardize care, expand access to cutting-edge treatments, and track patient outcomes through a comprehensive national registry.
The POPCaP Act of 2026 is a major upgrade to how the Department of Veterans Affairs (VA) handles prostate cancer, moving away from a one-size-fits-all approach toward 'precision oncology.' By January 1, 2027, the VA is required to establish a specialized program that uses genetic sequencing to tailor treatments to a veteran's specific DNA. The bill authorizes $15.5 million annually through 2029 to get the engine running, ensuring that any veteran diagnosed with prostate cancer can access high-tech diagnostics and clinical trials that were previously hard to find in the traditional system.
This isn't just a vague policy change; it’s a physical expansion of specialized medical hubs. The bill designates 26 specific VA medical facilities—ranging from Seattle to Gainesville—as 'provisional centers of excellence.' Under Section 2, the VA must keep at least 21 of these centers running at all times, with at least one in every regional network (VISN). For a veteran living in a rural area, this means the VA is now legally obligated to provide travel support so they can reach these centers to participate in biomarker-specific clinical trials. It turns a local VA visit into a gateway to a national network of specialists who meet monthly to discuss the latest research and complex cases via a telemedicine tumor board.
To make sure these centers aren't just 'centers of excellence' in name only, the bill sets strict staffing and tech requirements. Each center must employ a full squad: a medical oncologist, an interventional radiologist, a urologist, a radiation oncologist, a pathologist, and two research staffers. Beyond the people, the centers are required to establish 'metastasis biopsy capability' and use a uniform genetic sequencing platform. This means if a veteran moves from a center in Seattle to one in Florida, their genetic data and treatment plan will speak the same language, preventing the bureaucratic lag that often plagues large-scale healthcare systems.
The bill includes a 'trust but verify' mechanism for these medical centers. Starting in 2030, the Secretary will review up to seven centers a year on a rolling five-year cycle to ensure they are actually delivering results. If a center isn't meeting the mark, its designation can be pulled. To keep the public and Congress in the loop, the VA must report annually on the five-year survival rates of veterans in the program compared to civilians. This data-heavy approach is designed to prove whether the $15.5 million annual investment is actually extending lives, creating a transparent scoreboard for veteran healthcare outcomes.